WO2009069291A1 - Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke - Google Patents
Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke Download PDFInfo
- Publication number
- WO2009069291A1 WO2009069291A1 PCT/JP2008/003480 JP2008003480W WO2009069291A1 WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1 JP 2008003480 W JP2008003480 W JP 2008003480W WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prophylactic
- inhalation
- therapeutic composition
- tobacco smoke
- disease caused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is a prophylactic and/or therapeutic composition for chronic obstructive pulmonary disease (COPD) which is a disease caused by the inhalation of tobacco smoke. A composition is prepared, which comprises, as an active ingredient, at least one substance selected from the group consisting of orotic acid, orotidylic acid (a derivative of orotic acid), orotidine and uridine monophosphate (UMP), and inorganic salts and organic salts thereof. In the preparation, it is preferred that the composition be further added with an antioxidative agent, such as glutathione, N-acetylcysteine, coenzyme Q10, α-lipoic acid, vitamin C, vitamin E, polyphenol and carotenoid. The prophylactic and/or therapeutic composition can be administered orally or through inhalation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007305017A JP2011026204A (en) | 2007-11-26 | 2007-11-26 | Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke |
JP2007-305017 | 2007-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009069291A1 true WO2009069291A1 (en) | 2009-06-04 |
Family
ID=40678202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/003480 WO2009069291A1 (en) | 2007-11-26 | 2008-11-26 | Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2011026204A (en) |
WO (1) | WO2009069291A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012081604A1 (en) * | 2010-12-15 | 2012-06-21 | キリンホールディングス株式会社 | Composition containing orotic acid, and process for production thereof |
WO2016065419A1 (en) * | 2014-10-28 | 2016-05-06 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
WO2018207929A1 (en) * | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | Arterial oxygen saturation degree improver |
CN115814090A (en) * | 2022-11-22 | 2023-03-21 | 广州医科大学附属第一医院 | Novel medicine target spot for tobacco-induced inflammation |
US11890315B2 (en) | 2017-11-17 | 2024-02-06 | Renovion, Inc. | Stable ascorbic acid compositions and methods of using same |
CN115814090B (en) * | 2022-11-22 | 2024-05-24 | 广州医科大学附属第一医院 | Drug target for tobacco induced inflammation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2556832B1 (en) * | 2011-08-12 | 2017-07-19 | Universitätsklinikum Freiburg | Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease |
GB2524831A (en) * | 2014-04-04 | 2015-10-07 | Ermes Medical Company Ltd | New pharmaceutical use |
JP6811983B2 (en) * | 2016-08-18 | 2021-01-13 | 株式会社古川リサーチオフィス | Oral composition having retinal ganglion cell death inhibitory activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505553A (en) * | 1996-11-07 | 2001-04-24 | インスパイアー ファーマシューティカルズ,インコーポレイティド | Method of treating bronchitis with uridine triphosphate and related compounds |
WO2002100409A1 (en) * | 2001-06-11 | 2002-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Antiinflammatoric and antitussive compositions |
-
2007
- 2007-11-26 JP JP2007305017A patent/JP2011026204A/en active Pending
-
2008
- 2008-11-26 WO PCT/JP2008/003480 patent/WO2009069291A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505553A (en) * | 1996-11-07 | 2001-04-24 | インスパイアー ファーマシューティカルズ,インコーポレイティド | Method of treating bronchitis with uridine triphosphate and related compounds |
WO2002100409A1 (en) * | 2001-06-11 | 2002-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Antiinflammatoric and antitussive compositions |
Non-Patent Citations (5)
Title |
---|
"Encyclopedic Reference of Molecular Pharmacology", 2004, SPRINGER-VERLAG, pages: 784 - 790 * |
ANDERSON C.M. ET AL.: "Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, 1997, pages 387 - 392 * |
LAZAROWSKI E.R. ET AL.: "Direct Demonstration of Mechanically Induced Release of Cellular UTP and Its Implication for Uridine Nucleotide Receptor Activation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 39, 1997, pages 24348 - 24354 * |
PELS RIJCKEN W.R. ET AL.: "Pyrimidine metabolism and sugar nucleotide synthesis in rat liver", BIOCHEMICAL JOURNAL, vol. 266, 1990, pages 777 - 783 * |
SAIAG B. ET AL.: "Lack of uptake, release and action of UTP at sympathetic perivascular nerve terminals in rabbit ear artery", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 358, 1998, pages 139 - 145 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012081604A1 (en) * | 2010-12-15 | 2012-06-21 | キリンホールディングス株式会社 | Composition containing orotic acid, and process for production thereof |
WO2016065419A1 (en) * | 2014-10-28 | 2016-05-06 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
AU2015337800B2 (en) * | 2014-10-28 | 2021-05-27 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
US11135181B2 (en) | 2014-10-28 | 2021-10-05 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
WO2018207929A1 (en) * | 2017-05-12 | 2018-11-15 | 株式会社古川リサーチオフィス | Arterial oxygen saturation degree improver |
JPWO2018207929A1 (en) * | 2017-05-12 | 2020-01-23 | 株式会社古川リサーチオフィス | Arterial blood oxygen saturation enhancer |
US11331318B2 (en) | 2017-05-12 | 2022-05-17 | Furukawa Research Office Co., Ltd. | Arterial oxygen saturation degree improver |
US11890315B2 (en) | 2017-11-17 | 2024-02-06 | Renovion, Inc. | Stable ascorbic acid compositions and methods of using same |
CN115814090A (en) * | 2022-11-22 | 2023-03-21 | 广州医科大学附属第一医院 | Novel medicine target spot for tobacco-induced inflammation |
CN115814090B (en) * | 2022-11-22 | 2024-05-24 | 广州医科大学附属第一医院 | Drug target for tobacco induced inflammation |
Also Published As
Publication number | Publication date |
---|---|
JP2011026204A (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009069291A1 (en) | Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke | |
WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
NO20082124L (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
WO2008002245A3 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) | |
WO2008035359A3 (en) | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives | |
WO2007107470A3 (en) | Pyrazoles as 11-beta-hsd-1 | |
WO2007042786A3 (en) | 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
WO2009074950A3 (en) | Thiophene derivatives as agonists of s1p1/edg1 | |
SG156613A1 (en) | Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers | |
NZ592383A (en) | Pharmaceutical composition of a potent hcv inhibitor for oral administration | |
BRPI0719393B8 (en) | pharmaceutical composition | |
WO2007090882A3 (en) | Pharmaceutical extended release compositions comprising pramipexole | |
WO2007020204A3 (en) | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate | |
WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
NO20082047L (en) | Slow release composition, process for its preparation and use thereof | |
WO2011146583A3 (en) | Nanoparticulate cinacalcet formulations | |
WO2009051119A1 (en) | Pyrimidyl indoline compound | |
NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
WO2007093365A3 (en) | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | |
WO2007095043A3 (en) | Pharmaceutical formulations | |
MY143549A (en) | Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases | |
WO2010031832A3 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
WO2006077024A3 (en) | 5-aminoindole derivatives | |
NO20074933L (en) | Pharmaceutical composition comprising an indolylmaleimide derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08854676 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08854676 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |